By Dr Jonathan ShurlockEdited by Dr Saadia Aslam Remote monitoring of patients with heart failure (HF), via pulmonary artery pressure monitoring, is included in the…
View More Remote heart failure monitoring to improve quality of life and reduced hospitilisations: the MONITOR-HF trialAuthor: Sami Pratt
A coffee a day keeps the doctor away?
By Ahmed El-Medany Presented at ESC 2021 by Dr. Judit Simon, of the Heart and Vascular Centre, Semmelweis University, Budapest, Hungary; this large study included…
View More A coffee a day keeps the doctor away?Impaired retinal microvascular function predicts long-term adverse events in patients with cardiovascular disease
By Theuerle JD, Al-Fiadh AH et al Endothelial dysfunction is a precursor to the development of symptomatic atherosclerosis. Retinal microvascular reactivity to flicker light stimulation…
View More Impaired retinal microvascular function predicts long-term adverse events in patients with cardiovascular diseaseLow-temperature electrocautery reduces adverse effects from secondary cardiac implantable electronic device procedures: Insights from the WRAP-IT trial
By S Mittal et alTaken directly from Heart Rhythm Cardiac device procedures require tissue dissection to free existing device lead(s). The purpose of this study…
View More Low-temperature electrocautery reduces adverse effects from secondary cardiac implantable electronic device procedures: Insights from the WRAP-IT trialCurrent use and safety of novel oral anticoagulants in adults with congenital heart disease: results of a nationwide analysis including more than 44,000 patients
Dr Amit Bhan examines a study on Novel Oral Anticoagulants recently published in the European Heart Journal.
View More Current use and safety of novel oral anticoagulants in adults with congenital heart disease: results of a nationwide analysis including more than 44,000 patientsEnhanced Follow Up for Patients with Trifecta Aortic Valve Bioprostheses: A Statement from BHVS, SCTS and BCS
Statement following a Medical Device Alert issued by the MHRA
View More Enhanced Follow Up for Patients with Trifecta Aortic Valve Bioprostheses: A Statement from BHVS, SCTS and BCS